Harvard Medical School spinout TScan has come out of stealth with $48m in funding provided by investors including GV and two Novartis units.
TScan Therapeutics, a US-based oncology drug spinout of Harvard University, emerged from stealth on Wednesday with $48m in funding from investors including internet and technology conglomerate Alphabet and pharmaceutical firm Novartis.
The funding included a recent series B round of undisclosed size. The company’s investors include Alphabet unit GV and Novartis subsidiaries Novartis Venture Fund and Novartis Institutes of Biomedical Research (NIBR) as well as Bessemer Venture Partners and Longwood Fund.
TScan is developing cancer therapies that are…
